VIDEO: Olezarsen can reduce triglyceride levels in familial chylomicronemia syndrome
Click Here to Manage Email Alerts
ATLANTA — In this Healio video exclusive, Seth S. Martin, MD, MHS, FAHA, discusses research into lipid disorders from the American College of Cardiology Scientific Session, examining the Balance study on familial chylomicronemia syndrome.
Martin, a cardiologist at Johns Hopkins Hospital, professor of medicine at Johns Hopkins University School of Medicine and Healio | Cardiology Today Editorial Board Member, discussed the study, which tested the use of olezarsen (Ionis Pharmaceuticals) to reduce triglyceride levels in patients with the rare genetic disorder.
“I’d say this is an encouraging result for patients with [familial chylomicronemia syndrome]. And given there’s multiple drugs being developed, targeting ApoC-III for [familial chylomicronemia syndrome] but also for patients more broadly with elevated triglycerides, this is going to be a fun area to stay tuned in for because ... there’s good momentum here to better fulfill the clinical needs,” Martin said.
Collapse
Read more about
Click Here to Manage Email Alerts